tiprankstipranks
Advertisement
Advertisement
Upstream Bio presents new responder analyses from VIBRANT trial of verekitug
PremiumThe FlyUpstream Bio presents new responder analyses from VIBRANT trial of verekitug
2M ago
Upstream Bio downgraded to Neutral from Overweight at JPMorgan
Premium
The Fly
Upstream Bio downgraded to Neutral from Overweight at JPMorgan
2M ago
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor
Premium
Company Announcements
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor
2M ago
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
PremiumRatingsYaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
3M ago
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
Premium
The Fly
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
3M ago
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
Premium
The Fly
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
4M ago
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
PremiumThe FlyWix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
5M ago
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
Premium
The Fly
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
5M ago
Upstream Bio Launches $150 Million At-The-Market Program
Premium
Company Announcements
Upstream Bio Launches $150 Million At-The-Market Program
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100